Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia. Issue 10 (24th August 2021)

• Record Type: Journal Article
• Authors: Davids, Matthew S.; Telford, Claire; Abhyankar, Sarang; Waweru, Catherine; Ringshausen, Ingo
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 10(2021)
• Page Start: 2342
• Page End: 2351
• Publication Date: 2021-08-24
• Subjects: Acalabrutinib -- Bruton tyrosine kinase inhibitor -- chronic lymphocytic leukemia -- matching-adjusted indirect comparison -- targeted therapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1913144
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Acalabrutinib is a highly selective, potent, next-generation, covalent Bruton tyrosine kinase inhibitor with minimal off-target activity. Matching-adjusted indirect comparisons (MAICs) were performed to estimate the safety and efficacy of acalabrutinib compared to other targeted therapies for treatment-naïve patients with chronic lymphocytic leukemia (CLL). Individual patient data for acalabrutinib (ELEVATE-TN trial) were matched to aggregate baseline characteristics for comparators. After matching, acalabrutinib (with or without obinutuzumab) showed improved safety outcomes, except for increased risk of neutropenia ( p < 0.001) for acalabrutinib plus obinutuzumab versus ibrutinib and increased risk of leukopenia ( p < 0.05) for acalabrutinib (with or without obinutuzumab) versus venetoclax plus obinutuzumab. There was no statistically significant difference in progression-free survival between acalabrutinib (with or without obinutuzumab) and any of the comparators. This MAIC demonstrated a favorable safety profile for acalabrutinib-based therapy compared with other targeted therapies in treatment-naïve patients with CLL, without compromising efficacy.